piflufolastat (PYLARIFY) Report issue

Small molecule Imaging Approved FDA Priority Review FDA
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc([18F])nc1)C(=O)O)C(=O)O
  • InChIKey: OLWVRJUNLXQDSP-MVBOSPHXSA-N
  • Mol. Mass: 441.4
  • ALogP: 0.19
  • ChEMBL Molecules:
    piflufolastat f18  
    piflufolastat  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

18f dcfpyl | 18f-dcfpyl | dcfpyl

Organizations (29)

Research & Development (29)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Prostatic Neoplasms (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Genital Neoplasms, Female (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Neurilemmoma (Phase 1)

Prostatic Neoplasms (Phase 4)

Prostatic Neoplasms, Castration-Resistant (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 51
  • # of Trial Organizations: 29

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue